Evaluating measurable residual disease in acute myeloid leukemia
F Ravandi, RB Walter, SD Freeman - Blood advances, 2018 - ashpublications.org
Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …
Recent developments in immunotherapy of acute myeloid leukemia
The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer
treatment in the past decade, both in oncology and hematology. The transfer of the …
treatment in the past decade, both in oncology and hematology. The transfer of the …
An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance
Resistance to chemotherapy plays a significant role in cancer mortality. To identify genetic
units affecting sensitivity to cytarabine, the mainstay of treatment for acute myeloid leukemia …
units affecting sensitivity to cytarabine, the mainstay of treatment for acute myeloid leukemia …
[HTML][HTML] Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Background The powerful 'graft versus leukemia'effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia …
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia …
Review of applications of CRISPR-Cas9 gene-editing technology in cancer research
Z Zhao, C Li, F Tong, J Deng, G Huang… - Biological procedures …, 2021 - Springer
Characterized by multiple complex mutations, including activation by oncogenes and
inhibition by tumor suppressors, cancer is one of the leading causes of death. Application of …
inhibition by tumor suppressors, cancer is one of the leading causes of death. Application of …
Prognosis and characterization of immune microenvironment in acute myeloid leukemia through identification of an autophagy-related signature
Acute myeloid leukemia (AML) is one of the most common hematopoietic malignancies that
has an unfavorable outcome and a high rate of relapse. Autophagy plays a vital role in the …
has an unfavorable outcome and a high rate of relapse. Autophagy plays a vital role in the …
MIRROS: A randomized, placebo-controlled, Phase III trial of cytarabine±idasanutlin in relapsed or refractory acute myeloid leukemia
P Montesinos, BM Beckermann, O Catalani… - Future …, 2020 - Taylor & Francis
Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor
prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of …
prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of …
Selecting initial treatment of acute myeloid leukaemia in older adults
More than half of the patients with acute myeloid leukaemia (AML) are older than 60 years.
The treatment outcomes in this group remain poor with a median overall survival of< 1 year …
The treatment outcomes in this group remain poor with a median overall survival of< 1 year …
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
K Yee, C Papayannidis, N Vey, MJ Dickinson… - Leukemia research, 2021 - Elsevier
The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid
leukemia; thus, novel therapies are needed. We evaluated idasanutlin—a new, potent …
leukemia; thus, novel therapies are needed. We evaluated idasanutlin—a new, potent …
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
GJ Roboz, HM Kantarjian, KWL Yee, PL Kropf… - Cancer, 2018 - Wiley Online Library
BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia
(AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful …
(AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful …